Elevance Health, Inc. $ELV Shares Sold by Trillium Asset Management LLC

Trillium Asset Management LLC decreased its position in shares of Elevance Health, Inc. (NYSE:ELV) by 2.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 32,344 shares of the company’s stock after selling 679 shares during the quarter. Trillium Asset Management LLC’s holdings in Elevance Health were worth $12,580,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. GLOBALT Investments LLC GA boosted its holdings in shares of Elevance Health by 0.4% during the first quarter. GLOBALT Investments LLC GA now owns 6,306 shares of the company’s stock valued at $2,743,000 after acquiring an additional 24 shares during the period. Hemington Wealth Management increased its position in Elevance Health by 13.3% in the 1st quarter. Hemington Wealth Management now owns 230 shares of the company’s stock valued at $100,000 after acquiring an additional 27 shares during the period. Aspen Investment Management Inc increased its position in Elevance Health by 2.6% in the 1st quarter. Aspen Investment Management Inc now owns 1,048 shares of the company’s stock valued at $456,000 after acquiring an additional 27 shares during the period. Prudent Man Advisors LLC increased its position in Elevance Health by 2.3% in the 1st quarter. Prudent Man Advisors LLC now owns 1,257 shares of the company’s stock valued at $547,000 after acquiring an additional 28 shares during the period. Finally, Generali Investments Towarzystwo Funduszy Inwestycyjnych increased its position in Elevance Health by 5.3% in the 1st quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych now owns 600 shares of the company’s stock valued at $261,000 after acquiring an additional 30 shares during the period. Institutional investors and hedge funds own 89.24% of the company’s stock.

Wall Street Analysts Forecast Growth

ELV has been the topic of several analyst reports. Argus restated a “hold” rating on shares of Elevance Health in a research report on Monday, July 21st. UBS Group lowered their target price on Elevance Health from $435.00 to $425.00 and set a “buy” rating on the stock in a research report on Friday, September 5th. Leerink Partnrs cut Elevance Health from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. Bank of America lifted their price target on Elevance Health from $330.00 to $370.00 and gave the company a “neutral” rating in a research report on Friday, October 10th. Finally, Cowen reiterated a “buy” rating on shares of Elevance Health in a research report on Thursday, October 23rd. Twelve investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $397.33.

Elevance Health Stock Performance

Shares of NYSE ELV opened at $316.67 on Wednesday. The company has a quick ratio of 1.56, a current ratio of 1.56 and a debt-to-equity ratio of 0.71. The stock has a market capitalization of $70.38 billion, a price-to-earnings ratio of 12.95, a PEG ratio of 1.23 and a beta of 0.59. The stock’s fifty day simple moving average is $329.18 and its 200 day simple moving average is $346.39. Elevance Health, Inc. has a 52-week low of $273.71 and a 52-week high of $458.75.

Elevance Health (NYSE:ELV) last issued its earnings results on Tuesday, October 21st. The company reported $6.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.03 by $1.00. The business had revenue of $50.09 billion for the quarter, compared to analysts’ expectations of $49.26 billion. Elevance Health had a return on equity of 16.17% and a net margin of 2.84%.The company’s quarterly revenue was up 12.0% on a year-over-year basis. During the same period in the previous year, the firm posted $8.37 EPS. As a group, sell-side analysts forecast that Elevance Health, Inc. will post 33.96 earnings per share for the current fiscal year.

Elevance Health Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, December 19th. Investors of record on Friday, December 5th will be issued a $1.71 dividend. This represents a $6.84 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date is Friday, December 5th. Elevance Health’s payout ratio is presently 27.96%.

Insider Activity

In other Elevance Health news, Director Susan D. Devore bought 1,200 shares of the firm’s stock in a transaction dated Tuesday, August 19th. The stock was acquired at an average price of $312.15 per share, with a total value of $374,580.00. Following the completion of the transaction, the director directly owned 3,502 shares in the company, valued at approximately $1,093,149.30. This represents a 52.13% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.29% of the stock is owned by insiders.

Elevance Health Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.